Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

Rhea-AI Summary

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its financial and operational results for Q4 and full year 2023 on February 28, 2023, before market opening. A conference call/webcast is scheduled for 8:30 am ET the same day to discuss these results and offer a business update. Participants can join by dialing 877-407-9170 or accessing the audio webcast on Aurinia's website. The company, headquartered in Victoria, British Columbia, focuses on therapies for serious diseases, having launched LUPKYNIS® in January 2021, the first oral treatment approved by the FDA for active lupus nephritis.

Positive

• Aurinia is releasing Q4 and full-year results, indicating ongoing financial transparency.
• Conference call/webcast scheduled for 8:30 am ET provides opportunity for investor engagement.

Negative

• None.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday, February 28, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial 877-407-9170 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the audio webcast will be available on Aurinia’s website.

About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS^® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207006027/en/

Aurinia@westwicke.com

Source: Aurinia Pharmaceuticals Inc.

FAQ

When will Aurinia Pharmaceuticals release its Q4 2023 financial results?

Aurinia Pharmaceuticals will release its Q4 2023 financial results on February 28, 2023.

What time is the Aurinia Pharmaceuticals conference call for Q4 2023 results?

The conference call for Aurinia Pharmaceuticals' Q4 2023 results will be held at 8:30 am ET.

How can I listen to Aurinia Pharmaceuticals' financial results webcast?

The financial results webcast can be accessed through the Investors section of Aurinia's corporate website.

What is LUPKYNIS® and when was it launched?

LUPKYNIS® (voclosporin) is the first FDA-approved oral therapy for active lupus nephritis, launched by Aurinia in January 2021.